Day-one subcutaneous Leqembi gives early Alzheimer's patients a weekly at-home starting dose with benefits similar to IV treatment. Leqembi, the anti-amyloid drug lecanemab-irmb that clears amyloid plaques from the brain, can now be used subcutaneously for the full course.
The FDA approved Leqembi IQLIK as a starting dose on July 13, 2026, according to the Alzheimer's Association in the Association's approval announcement. The main benefit is convenience without travel for infusions. The main limits are narrow eligibility, brain-swelling risk, and long-term evidence that still comes mostly from IV treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changes with the shot?
- How well does it work?
- Who can be treated?
- What are the main risks?
- What evidence is still missing?
What changes with the shot?
The approved start is 500 mg once weekly as two back-to-back 250-mg autoinjector injections of about 15 seconds each. Eisai and Biogen said U.S. launch was planned for late August 2026 in the companies' approval statement.
After 18 months of initiation by IV or subcutaneous route, patients may move to 360 mg subcutaneously once weekly. That schedule replaces the prior path of IV-only start plus later maintenance. For families, the practical shift is fewer infusion-center visits during initiation. Storage, injection training, and dose timing still need a clear home routine.
How well does it work?
Weekly subcutaneous lecanemab reached drug exposure equal to IV dosing, supporting similar clinical benefit and plaque removal. Eisai reported in July 2026 that effects were consistent across body-weight groups with fixed dosing in the company's AAIC summary. Direct efficacy data come from the Phase 3 Clarity AD trial of IV lecanemab.
Patients declined 27% more slowly on CDR-SB than placebo at 18 months, a difference of -0.45 points, with strong amyloid reduction. That means the shot slows decline rather than stops or reverses symptoms. A 27% slower course can mean more months of independent daily function, but daily change may feel small.
Who can be treated?
Treatment is for early disease only: mild cognitive impairment or mild dementia with confirmed brain amyloid. Confirmation requires PET imaging or spinal-fluid testing.
People with moderate or advanced dementia do not qualify. Memory clinics usually review diagnosis, amyloid status, other health conditions, and medications before offering treatment. Useful checks before asking for referral:.
- diagnosis of MCI or mild dementia linked to Alzheimer's
- positive amyloid PET or spinal-fluid result
- ability to keep MRI visits and follow safety rules
- a care partner who can track doses and side effects
What are the main risks?
The key safety issue remains amyloid-related imaging abnormalities, or ARIA, which include brain swelling and tiny bleeds. Subcutaneous ARIA-E risk is expected to match IV, with no rise in isolated ARIA-H and mostly local injection reactions. ApoE ε4 carriers face higher ARIA risk.
Genetic testing and counseling help patients weigh that risk before starting. At-home dosing does not mean at-home monitoring. The FDA recommended an earlier extra MRI before the third dose to catch brain swelling sooner. Patients still need a strict in-clinic imaging schedule plus prompt reporting of headache, confusion, vision change, dizziness, or gait trouble.
What evidence is still missing?
Long-term subcutaneous outcomes rely heavily on bridging from IV trials and exposure matching. Real-world data on adherence, persistence, caregiver burden, and plaque clearance over years will take time. Weight-based questions look reassuring because fixed dosing held across weight groups in AAIC 2026 data.
Still, very low- or high-weight patients should discuss monitoring with their clinician. The most practical next step is a structured eligibility visit with amyloid confirmation, ApoE testing, MRI planning, and a written home-injection plan. Bring a medication list and a record of symptom onset.
You Might Also Like
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
